Stock 0GY1 SWEDISH ORPHAN BIOVITRUM
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company SWEDISH ORPHAN BIOVITRUM London S.E.

Equities

0GY1

Pharmaceuticals

End-of-day quote London S.E.
Other stock markets
- SEK - Intraday chart for SWEDISH ORPHAN BIOVITRUM
02/07 Sweden's Sobi Begins Rolling Application for Gout Treatment in US MT
02/07 Sobi Initiates Rolling Biologics License Application to FDA for SEL-212 for the Potential Treatment of Chronic Refractory Gout CI

Business Summary

Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.

Sales per Business

SEK in Million2022Weight2023Weight Delta
Haematology
60.4 %
10,831 57.6 % 13,370 60.4 % +23.44%
Immunology
34.5 %
6,679 35.5 % 7,635 34.5 % +14.31%
Specialty Care
5.1 %
1,280 6.8 % 1,119 5.1 % -12.58%

Sales per region

SEK in Million2022Weight2023Weight Delta
United States
36.8 %
7,364 39.2 % 8,148 36.8 % +10.65%
Europe
35.5 %
3,585 19.1 % 7,851 35.5 % +119.00%
Global
12.3 %
1,427 7.6 % 2,718 12.3 % +90.47%
Rest of the World
12.0 %
2,438 13.0 % 2,653 12.0 % +8.82%
Sweden
3.0 %
667 3.5 % 660 3.0 % -1.05%
North America
0.4 %
77 0.4 % 93 0.4 % +20.78%

Managers

Managers TitleAgeSince
Guido Oelkers CEO
 Chief Executive Officer 59 22/17/22
Henrik Stenqvist DFI
 Director of Finance/CFO 57 20/18/20
Lydia Abad-Franch CTO
 Chief Tech/Sci/R&D Officer - -
Christine Wesström CTO
 Chief Tech/Sci/R&D Officer 49 01/10/01
Sven Anders Ullman BRD
 Director/Board Member 68 01/21/01
Pablo de Mora SAM
 Sales & Marketing 56 01/19/01
Daniel Rankin PRN
 Corporate Officer/Principal 44 01/17/01
Mahmood Ladha PRN
 Corporate Officer/Principal 60 01/19/01
Norbert Oppitz PRN
 Corporate Officer/Principal 57 02/17/02
Armin Reininger PRN
 Corporate Officer/Principal 67 06/17/06

Members of the board

Members of the board TitleAgeSince
Sven Anders Ullman BRD
 Director/Board Member 68 01/21/01
Annette Clancy CHM
 Chairman 70 08/14/08
Staffan Schüberg BRD
 Director/Board Member 55 01/20/01
Helena Ildiko Saxon BRD
 Director/Board Member 54 05/11/05
Filippa Stenberg BRD
 Director/Board Member - -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 1,621,178 0 1,621,178 ( 100.00 %) 50.90 %
Stock B 1 354,358,946 181,180,760 ( 51.13 %) 14,490,831 ( 4.089 %)

Shareholders

NameEquities%Valuation
Investor AB (Investment Company)
34.70 %
122,964,760 34.70 % 3 302 M kr
ASTRAZENECA PLC
9.889 %
35,043,624 9.889 % 941 M kr
Fjärde AP-fonden
5.929 %
21,010,927 5.929 % 564 M kr
SWEDISH ORPHAN BIOVITRUM AB
4.121 %
14,601,832 4.121 % 392 M kr
Handelsbanken Fonder AB
2.200 %
7,795,896 2.200 % 209 M kr
Swedbank Robur Fonder AB
1.799 %
6,373,879 1.799 % 171 M kr
Folksam
1.022 %
3,622,891 1.022 % 97 M kr
Nordea Investment Management AB
0.9359 %
3,316,305 0.9359 % 89 M kr
Länsförsäkringar Fondförvaltning AB
0.8589 %
3,043,525 0.8589 % 82 M kr
Carnegie Fonder AB
0.7912 %
2,803,642 0.7912 % 75 M kr

Holdings

NameEquities%Valuation
SWEDISH ORPHAN BIOVITRUM AB
4.12%
 14,601,832 4.12% 392,077,441 $

Company contact information

Swedish Orphan Biovitrum AB

Tomtebodavägen 23A

112 76, Solna

+46 86 97 20 00

http://www.sobi.com
address SWEDISH ORPHAN BIOVITRUM(0GY1)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per Business

Sales per region

Sector Biopharmaceuticals

1st Jan change Capi.
CSL LIMITED Stock CSL Limited
+4.57% 9.77TCr
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+5.66% 4.14TCr
BIOGEN INC. Stock Biogen Inc.
-12.80% 3.29TCr
UCB Stock UCB
+80.99% 2.93TCr
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-15.53% 1.55TCr
INCYTE CORPORATION Stock Incyte Corporation
-8.70% 1.29TCr
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.22% 1.15TCr
ALTEOGEN INC. Stock ALTEOGEN Inc.
+183.25% 1.07TCr
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-55.41% 897.35Cr
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. SOBI Stock
  4. 0GY1 Stock
  5. Company SWEDISH ORPHAN BIOVITRUM